Cargando…
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study
BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase gene rearrangements (ALKr) resulting in EML4–ALK proteins occur in a subset of solid tumors and are targeted by ALK inhibitors. Given the development of drug resistance to ALK inhibitors, ALK inhibitors with different kinase selectivity are requir...
Autores principales: | Ono, Akira, Murakami, Haruyasu, Seto, Takashi, Shimizu, Toshio, Watanabe, Sawori, Takeshita, Shigeru, Takeda, Kentaro, Toyoshima, Junko, Nagase, Itsuro, Bahceci, Erkut, Morishita, Maiko, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937589/ https://www.ncbi.nlm.nih.gov/pubmed/33331996 http://dx.doi.org/10.1007/s40268-020-00331-2 |
Ejemplares similares
-
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
por: Li, Tianhong, et al.
Publicado: (2016) -
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015) -
The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014) -
Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations
por: Murakami, Haruyasu, et al.
Publicado: (2018) -
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
por: Azuma, Koichi, et al.
Publicado: (2018)